drugset / Trial / NCT00610727
Staccato Prochlorperazine Single Dose PK Study
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this study was to evaluate the tolerability, safety, and pharmacokinetics of inhaled prochlorperazine
Timeline
- Start
- 2004-08
- Primary completion
- 2004-10
- Completion
- 2004-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Prochlorperazine | Small molecule | 0.5 mg | Intravenous |
| Subject | Prochlorperazine | Small molecule | 0.625 mg | Intravenous |
| Subject | Prochlorperazine | Small molecule | 1.25 mg | Intravenous |
| Subject | Prochlorperazine | Small molecule | 2.5 mg | Intravenous |
| Subject | Prochlorperazine | Small molecule | 5 mg | Intravenous |
| Subject | Prochlorperazine | Small molecule | 10 mg | Intravenous |